Volume 18, Issue 3 (September 2020)                   Iranian Rehabilitation Journal 2020, 18(3): 293-300 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mirabzadeh A, Iranpour H R, Khorram Khorshid H R, Zare-Abdollahi D, Norouzi M, Vatankhah V. Investigation of DRD2 and HTR2A mRNA Expression in Two Therapeutic States of Antipsychotic Polypharmacy and Aripiprazole Monotherapy in the Peripheral Blood of Patients With Schizophrenia. Iranian Rehabilitation Journal. 2020; 18 (3) :293-300
URL: http://irj.uswr.ac.ir/article-1-1052-en.html
1- Social Determinants of Health Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
2- Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran.
3- Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
4- Imam Khomeini Hospital Complex of Firuzkuh, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract:   (648 Views)
Objectives: Schizophrenia is a severe psychiatric disorder that has profound effects on both individuals and the community. Notwithstanding the suggestion for treating schizophrenia with a minimum dose of drugs, antipsychotic polypharmacy increases the patient’s care costs and drug interactions. Aripiprazole reduces the metabolic side effects of antipsychotic polypharmacy treatment. DRD2 and HTR2A can serve as predictors for response to treatment in schizophrenic patients. The purpose of this survey was to measure the DRD2 and HTR2A genes expression in the peripheral blood samples using Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR).
Methods: A total of 19 patients with a long history of schizophrenia who received at least two types of antipsychotics with daily doses of more than 500 mg of chlorpromazine were entered into the study. The response rates to the treatment based on scores in the Brief Psychiatric Rating Scale (BPRS) questionnaire and DRD2 and HTR2A expression were compared between antipsychotic polypharmacy status and 6 months after monotherapy with aripiprazole.
Results: The levels of DRD2 expression decreased significantly after the intervention. The mean changes in HTR2A expression and the BPRS questionnaire and also the relationship between changes in DRD2 and HTR2A expression and changes in BPRS score after the intervention were not significant.
Discussion: The conversion of the antipsychotic polypharmacy state to monotherapy with aripiprazole has been accompanied by a significant decrease in DRD2A expression. These genes can be used for evaluating the response rate of schizophrenia treatments in the future.
Full-Text [PDF 675 kb]   (328 Downloads) |   |   Full-Text (HTML)  (167 Views)  
Article type: Original Research Articles | Subject: Psychiatry
Received: 2019/08/2 | Accepted: 2020/08/2 | Published: 2020/09/1

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb